Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients

INTRODUCTION: Advances in genomic techniques have been valuable in guiding decisions regarding the treatment of early breast cancer (EBC) patients. These multigene assays include Oncotype DX, Prosigna, and Endopredict. There has generally been a tendency to overtreat or undertreat patients, and havi...

Descripción completa

Detalles Bibliográficos
Autores principales: Assi, Hazem I., Alameh, Ibrahim A., Khoury, Jessica, Abdul Halim, Nour, El Karak, Fadi, Farhat, Fadi, Berro, Juliett, Sbaity, Eman, Charafeddine, Maya, Tfayli, Arafat, Salem, Ziad, El Saghir, Nagi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719508/
https://www.ncbi.nlm.nih.gov/pubmed/33312202
http://dx.doi.org/10.1155/2020/9238084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719508/
https://www.ncbi.nlm.nih.gov/pubmed/33312202
http://dx.doi.org/10.1155/2020/9238084

Ejemplares similares